{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-114414","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.610569+00:00","generated_at":"2026-06-22T08:38:46.731766+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Iovance Q3 net loss $99.6M ($0.63/sh); BLA submission for lifileucel on track to complete in Q4 2022","bullets":["Cash, equivalents, investments & restricted cash $366.6M at Sep 30, 2022, down from $602.1M at Dec 31, 2021; runway into 2024.","Net loss $99.6M vs $86.1M YoY; R&D expense $72.5M (+$7.1M), G&A $27.9M (+$7.0M).","Rolling BLA for lifileucel in advanced melanoma started August 2022, expected to complete in Q4 2022.","Phase 3 trial of lifileucel + pembrolizumab in frontline advanced melanoma on track to begin late 2022.","iCTC facility annual capacity for 2,000+ patients; new cGMP manufacturing suites for commercial supply."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-114414","json":"https://secwatch.observer/filing/0001104659-22-114414.json","markdown":"https://secwatch.observer/filing/0001104659-22-114414.md","text":"https://secwatch.observer/filing/0001104659-22-114414.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465922114414/0001104659-22-114414-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465922114414/tm2229606d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:38:46.731766+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dcc0886d2c5f220c6b71f3bf5008b2a66f322dca","claim":"IOVANCE BIOTHERAPEUTICS, INC. reported the quarter ended September 30, 2022 results: net income $99.6 million, or $0.63 per share, EPS $0.63 per share.","evidence_excerpt":"Net loss for the third quarter ended September 30, 2022, was $99.6 million, or $0.63 per share, compared to a net loss of $86.1 million, or $0.55 per share, for the third quarter ended September 30, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465922114414/0001104659-22-114414-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Net income","value":"$99.6 million, or $0.63 per share"},{"label":"EPS","value":"$0.63 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}